A new study has identified targets to fight common cold.
Scientists from Procter & Gamble (P&G), the University of Calgary and the University of Virginia have announced results from the first study to examine the entire human genome's response to the most common cold virus, human rhinovirus.
The common cold is the most common illness worldwide, affecting the average global adult two to five times each year. Rhinoviruses are responsible for approximately 30 to 50 percent of all common cold cases. The rhinovirus types are most active in the fall and winter and have two modes of transmission: by touching surfaces that have been contaminated with cold virus and then touching your eyes or nose, or by inhaling droplets of cold virus from the air.
The research confirmed, at the genomic level, that the immune system response to the virus, and not the virus by itself, results in common cold symptoms. Data generated by the study will be crucial in the search for new treatments for the common cold, which is the most common illness worldwide, affecting billions of people every year.
Specifically, the study identifies several categories of therapeutic targets that could balance the immune response in order to minimize symptoms during an infection and potentially even lead to therapies that may prevent infection.
In the randomized, placebo-controlled study, researchers infected 17 volunteers with rhinovirus-16 and an additional 18 volunteers (who served as the study control group) were given a sham inoculation in the form of a nasal saline spray.